Can a skin cream make immunotherapy more effective?
NCT ID NCT05481658
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a topical cream called diphencyprone (DPCP) can help standard immunotherapy work better in people with advanced cancer that has spread to the skin. About 100 participants will apply DPCP twice a week for 12 weeks alongside their usual PD-1 or PD-L1 inhibitor treatment. The main goals are to check safety and to see how the cream changes immune activity in the skin tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diphencyprone (DPCP) topical cream
What this could lead to
If successful, this could point toward a way to make immunotherapy work better for people with skin metastases from advanced cancer.
What could go wrong
This is a very early Phase I trial with only 100 participants, focused on safety and immune markers, not on curing the cancer. The combination may cause skin reactions or other side effects, and it is unknown if it will improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact